CL2011001927A1 - Uso de una composicion farmaceutica de liberacion sostenida, que comprende como ingrediente activo a 4-aminopiridina, que sirve para preparar un medicamento util para el tratamiento de la esclerosis multiple, en dos dosis de 10 miligramos diarias, que permite recuperar la marcha de un paciente afectado. - Google Patents
Uso de una composicion farmaceutica de liberacion sostenida, que comprende como ingrediente activo a 4-aminopiridina, que sirve para preparar un medicamento util para el tratamiento de la esclerosis multiple, en dos dosis de 10 miligramos diarias, que permite recuperar la marcha de un paciente afectado.Info
- Publication number
- CL2011001927A1 CL2011001927A1 CL2011001927A CL2011001927A CL2011001927A1 CL 2011001927 A1 CL2011001927 A1 CL 2011001927A1 CL 2011001927 A CL2011001927 A CL 2011001927A CL 2011001927 A CL2011001927 A CL 2011001927A CL 2011001927 A1 CL2011001927 A1 CL 2011001927A1
- Authority
- CL
- Chile
- Prior art keywords
- multiple sclerosis
- aminopyridine
- gait
- doses
- recovery
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 3
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229960004979 fampridine Drugs 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 230000005021 gait Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000011084 recovery Methods 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000003319 supportive effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15167909P | 2009-02-11 | 2009-02-11 | |
| US25956309P | 2009-11-09 | 2009-11-09 | |
| US28587209P | 2009-12-11 | 2009-12-11 | |
| US28895309P | 2009-12-22 | 2009-12-22 | |
| US29925910P | 2010-01-28 | 2010-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011001927A1 true CL2011001927A1 (es) | 2012-07-20 |
Family
ID=42562065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011001927A CL2011001927A1 (es) | 2009-02-11 | 2011-08-10 | Uso de una composicion farmaceutica de liberacion sostenida, que comprende como ingrediente activo a 4-aminopiridina, que sirve para preparar un medicamento util para el tratamiento de la esclerosis multiple, en dos dosis de 10 miligramos diarias, que permite recuperar la marcha de un paciente afectado. |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20120029035A1 (OSRAM) |
| JP (1) | JP2012517449A (OSRAM) |
| KR (3) | KR20170034452A (OSRAM) |
| CN (2) | CN102046174A (OSRAM) |
| AR (1) | AR075413A1 (OSRAM) |
| AU (2) | AU2010213663A1 (OSRAM) |
| BR (2) | BRPI1000030A2 (OSRAM) |
| CA (1) | CA2751581A1 (OSRAM) |
| CL (1) | CL2011001927A1 (OSRAM) |
| CO (1) | CO6440534A2 (OSRAM) |
| EA (1) | EA022755B1 (OSRAM) |
| EC (1) | ECSP11011311A (OSRAM) |
| IL (1) | IL214500A0 (OSRAM) |
| MX (1) | MX2011008485A (OSRAM) |
| NI (1) | NI201100155A (OSRAM) |
| NZ (1) | NZ595046A (OSRAM) |
| PE (1) | PE20120791A1 (OSRAM) |
| SG (2) | SG10201609184PA (OSRAM) |
| TN (1) | TN2011000403A1 (OSRAM) |
| TW (2) | TW201032809A (OSRAM) |
| UY (2) | UY32444A (OSRAM) |
| WO (2) | WO2010093838A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| US20150111930A1 (en) * | 2013-10-23 | 2015-04-23 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
| TW201125562A (en) * | 2009-09-04 | 2011-08-01 | Acorda Therapeutics Inc | Sustained release fampridine treatment in patients with multiple sclerosis |
| CN102442942A (zh) * | 2010-10-08 | 2012-05-09 | 天津和美生物技术有限公司 | 4-氨基吡啶的多晶型物及其制备和应用 |
| EP2995305B1 (en) * | 2011-01-28 | 2020-03-04 | Acorda Therapeutics, Inc. | Use of potassium channel blockers to treat cerebral palsy |
| EP3381455A1 (en) * | 2012-02-13 | 2018-10-03 | Acorda Therapeutics, Inc. | Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine |
| WO2014028387A1 (en) * | 2012-08-13 | 2014-02-20 | Acorda Therapeutics, Inc. | Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine |
| EP3103096A4 (en) * | 2014-02-04 | 2018-01-03 | Optimata Ltd. | Method and system for prediction of medical treatment effect |
| RU2580837C1 (ru) * | 2015-05-05 | 2016-04-10 | Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" | Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе |
| US10172842B2 (en) | 2015-09-11 | 2019-01-08 | PharmaDax Inc. | Sustained release oral dosage form containing dalfampridine |
| WO2022124946A1 (ru) * | 2020-12-10 | 2022-06-16 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Новые полиморфные формы 4-аминопиридина и их фармацевтическое применение |
| CN112914884B (zh) * | 2021-01-19 | 2022-02-11 | 重庆火后草科技有限公司 | 通过稳态时长置信度测量睡眠状态下的体重值的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
| US6288026B1 (en) * | 1999-02-24 | 2001-09-11 | Heinrich Exner | Process and composition for treating diseases with an oil-in-water emulsion |
| US8007826B2 (en) * | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) * | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
-
2010
- 2010-02-11 BR BRPI1000030A patent/BRPI1000030A2/pt not_active IP Right Cessation
- 2010-02-11 EA EA201171043A patent/EA022755B1/ru unknown
- 2010-02-11 KR KR1020177007639A patent/KR20170034452A/ko not_active Ceased
- 2010-02-11 SG SG10201609184PA patent/SG10201609184PA/en unknown
- 2010-02-11 UY UY0001032444A patent/UY32444A/es not_active Application Discontinuation
- 2010-02-11 KR KR1020117021266A patent/KR20120000560A/ko not_active Ceased
- 2010-02-11 PE PE2011001475A patent/PE20120791A1/es not_active Application Discontinuation
- 2010-02-11 WO PCT/US2010/023969 patent/WO2010093838A1/en not_active Ceased
- 2010-02-11 CA CA2751581A patent/CA2751581A1/en not_active Abandoned
- 2010-02-11 SG SG2011057783A patent/SG173641A1/en unknown
- 2010-02-11 TW TW099104401A patent/TW201032809A/zh unknown
- 2010-02-11 JP JP2011549357A patent/JP2012517449A/ja active Pending
- 2010-02-11 NZ NZ595046A patent/NZ595046A/xx not_active IP Right Cessation
- 2010-02-11 CN CN201080000861XA patent/CN102046174A/zh active Pending
- 2010-02-11 CN CN2010800008624A patent/CN101896182A/zh active Pending
- 2010-02-11 US US13/148,231 patent/US20120029035A1/en not_active Abandoned
- 2010-02-11 TW TW099104403A patent/TW201034665A/zh unknown
- 2010-02-11 KR KR1020187029188A patent/KR20180114250A/ko not_active Ceased
- 2010-02-11 BR BRPI1000031A patent/BRPI1000031A2/pt not_active Application Discontinuation
- 2010-02-11 AU AU2010213663A patent/AU2010213663A1/en not_active Abandoned
- 2010-02-11 UY UY0001032445A patent/UY32445A/es not_active Application Discontinuation
- 2010-02-11 MX MX2011008485A patent/MX2011008485A/es not_active Application Discontinuation
- 2010-02-11 WO PCT/US2010/023970 patent/WO2010093839A1/en not_active Ceased
- 2010-02-12 AR ARP100100402A patent/AR075413A1/es unknown
-
2011
- 2011-08-07 IL IL214500A patent/IL214500A0/en unknown
- 2011-08-09 NI NI201100155A patent/NI201100155A/es unknown
- 2011-08-10 TN TN2011000403A patent/TN2011000403A1/fr unknown
- 2011-08-10 CL CL2011001927A patent/CL2011001927A1/es unknown
- 2011-09-08 EC EC2011011311A patent/ECSP11011311A/es unknown
- 2011-09-09 CO CO11116663A patent/CO6440534A2/es not_active Application Discontinuation
-
2014
- 2014-11-26 US US14/555,487 patent/US20150313886A1/en not_active Abandoned
-
2016
- 2016-08-25 AU AU2016219650A patent/AU2016219650C1/en not_active Ceased
-
2017
- 2017-05-17 US US15/597,991 patent/US20170319562A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011001927A1 (es) | Uso de una composicion farmaceutica de liberacion sostenida, que comprende como ingrediente activo a 4-aminopiridina, que sirve para preparar un medicamento util para el tratamiento de la esclerosis multiple, en dos dosis de 10 miligramos diarias, que permite recuperar la marcha de un paciente afectado. | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| SV2010003451A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
| ECSP14013217A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk. | |
| ECSP13012467A (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| MX2019007956A (es) | Liberacion autorregulada de ingrediente farmaceutico activo. | |
| CU20110100A7 (es) | Tratamiento de pirfenidona para pacientes con función hepática atípica | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| GT200600445A (es) | Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo. | |
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
| AR059359A1 (es) | Formulaciones farmaceuticas que contienen pleconaril | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| CR20140005A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| CR20110243A (es) | Tratamiento de pirfenidona para pacientes con función hepática. | |
| EA201391689A1 (ru) | Система доставки лекарственного средства | |
| CY1118158T1 (el) | Δευτεριωμενα 1-πιπεραζινο-3-φαινυλικα ινδανια για τη θεραπευτικη αντιμετωπιση της σχιζοφρενιας | |
| PE20151607A1 (es) | Formulaciones de compuestos organicos | |
| UY31768A (es) | Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre | |
| CL2010001577A1 (es) | Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. |